Birte K. Skrumsager

Immunology and Microbiology · Life Sciences

11h-index833citations29works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(8), Immune Cell Function and Interaction(6), CAR-T cell therapy research(6), Schizophrenia research and treatment(4), Neurotransmitter Receptor Influence on Behavior(4)

Publications29 total

Data from Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial
2023Open Access
Data from Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial
2023Open Access
Supplementary Figures S1-S3 from Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial
2023Open Access
Supplementary Figures S1-S3 from Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial
2023Open Access
Safety, PK, and PD of recombinant anti-interleukin-21 monoclonal antibody in a first-in-human trial
International Journal of Clinical Pharmacology and Therapeutics·2016· 43 cited
SAT0254 Safety and Tolerability of the Anti-C5ar Humanised Monoclonal Antibody NNC0151-0000 in Patients with Rheumatoid Arthritis: A Phase 2, Randomised, Double-Blind, Placebo-Controlled, Multiple-Dose Trial
Annals of the Rheumatic Diseases·2014· 1 cited
Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial
Clinical Cancer Research·2009· 138 cited
Activity of recombinant human interleukin-21 (rIL-21) in patients (pts) with stage IV malignant melanoma (MM) without prior treatment: Clinical data from a phase IIa study
Journal of Clinical Oncology·2008· 7 cited
IL-21 induces in vivo immune activation of NK cells and CD8+ T cells in patients with metastatic melanoma and renal cell carcinoma
Cancer Immunology Immunotherapy·2008· 114 citedOpen Access
OR.85. Leukocyte Responses during Recombinant Human Interleukin-21 Treatment of Patients with Stage IV Melanoma
Clinical Immunology·2008
Anti-tumor activity of recombinant human Interleukin-21 (rIL-21): Preliminary data from a phase 2a study in patients with stage IV malignant melanoma (MM) without prior treatment
Journal of Clinical Oncology·2007
An Open-Label, Two-Arm, Phase I Trial of Recombinant Human Interleukin-21 in Patients with Metastatic Melanoma
Clinical Cancer Research·2007· 165 citedOpen Access
Combined Pharmacodynamic and Transcriptome Profiling of Recombinant Human Interleukin-21 Responses in Patients with Stage IV Malignant Melanoma
Clinical Immunology·2007
265 POSTER Recombinant human Interleukin-21 (rIL-21), a new cytokine for immunotherapy: results of two phase 1 studies in patients with metastatic melanoma (MM) or renal cell carcinoma (RCC)
European Journal of Cancer Supplements·2006· 2 cited
Sa.54. Interleukin-21: Intravenous Administration of Interleukin-21 Leads to Immune Activation in Humans-Preliminary Results from a Phase 1 Trial
Clinical Immunology·2006· 1 cited
Ragaglitazar: The Pharmacokinetics, Pharmacodynamics, and Tolerability of a Novel Dual PPARα and γ Agonist in Healthy Subjects and Patients with Type 2 Diabetes
The Journal of Clinical Pharmacology·2003· 48 cited
Safety and Pharmacokinetics of ReN1869: A First Human Dose Study in Healthy Subjects after Single‐Dose Administration
The Journal of Clinical Pharmacology·2003· 6 cited
Levormeloxifene: safety, pharmacodynamics and pharmacokinetics in healthy postmenopausal women following single and multiple doses of a new selective oestrogen receptor modulator
British Journal of Clinical Pharmacology·2002· 18 citedOpen Access
Levormeloxifene: Safety & pharmacokinetics in young versus elderly postmenopausal women
Clinical Pharmacology & Therapeutics·1999
NNC 01-0687, a selective dopamine D1 receptor antagonist, in the treatment of schizophrenia
Psychopharmacology·1995· 52 cited
page 1 of 2Next →

Frequent Co-authors

Ian D. Davis(13), Grant A. McArthur(12), Kresten Skak(10), Dorthe Lundsgaard(10), Klaus Stensgaard Frederiksen(10), Ulrik Mouritzen(10), Lasse Tengbjerg Hansen(8), Paul E.G. Kristjansen(8), Jonathan Cebon(7), Michael Millward(5), Ben Brady(4), Richard F. Kefford(4), Ben Brady(2), Richard Kefford(2), Per Karlsson(2), Lars Farde(2), Christer Halldin(2), Christian Foged(2), Jesper Karle(2), Henrik Lublin(2)